Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · colon-landscapes@1

SRR15030893

—

71368cd3-22b3-58da-93df-da6389bf5a57

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
  • UV_RESPONSE_DN+0.380
  • PROTEIN_SECRETION+0.360
  • ALLOGRAFT_REJECTION+0.330
  • KRAS_SIGNALING_UP+0.310
  • TGF_BETA_SIGNALING+0.290
  • HEDGEHOG_SIGNALING+0.230
  • INTERFERON_GAMMA_RESPONSE+0.210
  • INFLAMMATORY_RESPONSE+0.200
  • NOTCH_SIGNALING+0.200

Top 10 suppressed

  • MYC_TARGETS_V2-0.340
  • GLYCOLYSIS-0.290
  • KRAS_SIGNALING_DN-0.270
  • UV_RESPONSE_UP-0.270
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.260
  • PANCREAS_BETA_CELLS-0.250
  • BILE_ACID_METABOLISM-0.230
  • DNA_REPAIR-0.230
  • FATTY_ACID_METABOLISM-0.230
  • XENOBIOTIC_METABOLISM-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8613704
breast-umap@18
—A0.805
2TCGA-CR-7382-01A-11R-2132-07
head-neck@1
——0.795
3SRR15030887
colon-landscapes@1
——0.793
4TCGA-BH-A1EO-01A-11R-A137-07
breast-umap@18
—A0.792
5TCGA-EW-A1IY-01A-11R-A13Q-07
breast-umap@18
—B0.787
6ad478846-0a75-4081-ac09-37ee5415d9b4
colon-landscapes@1
——0.782
7SRR10900557
melanoma-umap@29
——0.779
8SRR6013569
lung-landscapes@6
—cohortMD20.776
9SRR4195664
colon-landscapes@1
——0.773
106a43f966-cb2b-47ee-b0f4-c269707daa88
melanoma-umap@29
——0.773

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 23 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.400Inavolisib— uncovered
UV_RESPONSE_DN0.380Inavolisib— uncovered
PROTEIN_SECRETION0.360Remibrutinib— uncovered
ALLOGRAFT_REJECTION0.330Idelalisib— uncovered
KRAS_SIGNALING_UP0.310Inavolisib— uncovered
TGF_BETA_SIGNALING0.290Inavolisib— uncovered
HEDGEHOG_SIGNALING0.230Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.210Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.200Idelalisib— uncovered
NOTCH_SIGNALING0.200Inavolisib— uncovered
COMPLEMENT0.180Inavolisib— uncovered
ANGIOGENESIS0.170Remibrutinib— uncovered
ANDROGEN_RESPONSE0.150Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.150Inavolisib— uncovered
IL2_STAT5_SIGNALING0.140Idelalisib— uncovered
MITOTIC_SPINDLE0.130Inavolisib— uncovered
APOPTOSIS0.120Idelalisib— uncovered
HEME_METABOLISM0.120Temsirolimus— uncovered
MYOGENESIS0.110Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.050Inavolisib— uncovered